QUALIGEN
Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform.
QUALIGEN
Industry:
Biotechnology
Founded:
1996-01-01
Address:
Carlsbad, California, United States
Country:
United States
Website Url:
http://www.qualigeninc.com
Total Employee:
11+
Status:
Active
Contact:
760-579-6900
Total Funding:
30.82 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Geneius
Geneius is a Biotechnology company.
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
Septerna
Septerna is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Board_member
Board_member
2020-12-01
Current Employees Featured
Amy Broidrick Executive Vice President & Chief Strategy Officer @ Qualigen
Executive Vice President & Chief Strategy Officer
2020-12-01
Christopher L. Lotz VP & Chief Financial Officer @ Qualigen
VP & Chief Financial Officer
Tariq Arshad Chief Medical Officer, Senior Vice President @ Qualigen
Chief Medical Officer, Senior Vice President
2021-05-01
Shishir Sinha Sr. Vice President & Chief Operating Officer @ Qualigen
Sr. Vice President & Chief Operating Officer
2022-01-01
Michael S. Poirier Founder ,President, CEO & Chairman @ Qualigen
Founder ,President, CEO & Chairman
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-05-03 | Nanosynex | Nanosynex acquired by Qualigen | N/A |
| 2020-05-26 | Ritter Pharmaceuticals | Ritter Pharmaceuticals acquired by Qualigen | N/A |
Key Employee Changes
Official Site Inspections
http://www.qualigeninc.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Qualigen"
Qualigen - Crunchbase Company Profile & Funding
Contact Email systemsupport@qualigeninc.com Phone Number 760-579-6900 Qualigen is a biotechnology company focused on the development and commercialization of novel …See details»
Our Company - Qualigen Therapeutics
Change Qualigen aims to change the status quo. Qualigen delivers change through science for life. Create Qualigen Therapeutics strives to create treatments that propel hope and improved outcomes. We enable patients for …See details»
Home - Qualigen Therapeutics
Our Approach Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. We have three investigational oncology …See details»
Qualigen Diagnostics - Home of the FastPack
Qualigen Therapeutics - LinkedIn
Qualigen Therapeutics | 1,393 followers on LinkedIn. Driven to Deliver | Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing …See details»
Qualigen Company Profile - Office Locations, Competitors ... - Craft
See insights on Qualigen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce ... - Nasdaq
Jan 21, 2020 Management and Organization. ... Qualigen, Inc. (www.qualigeninc.com) is a biotechnology company focused on developing novel therapeutics for the treatment of cancer …See details»
Qualigen Therapeutics Engages TD2 as Contract Research …
Mar 30, 2022 TD2 is a precision oncology drug development organization integrating preclinical, clinical, and regulatory expertise and providing expert drug development services, including …See details»
Qualigen Therapeutics: Where It All Started And Where It's Going …
Oct 8, 2022 In this episode of BioTech IQ, Ammon Rivera continues his exploration of Qualigen Therapeutics by interviewing the founder and CEO of the company Michael Porier.Michael …See details»
Qualigen Therapeutics CEO Michael Poirier Provides Letter to …
CARLSBAD, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and …See details»
Qualigen Therapeutics Chief Executive Officer Michael Poirier …
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused …See details»
Qualigen, Inc. (Qualigen, Inc.) - 药物管线_专利_临床试验_投融营收
CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric …See details»
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial ...
Nov 15, 2022 Qualigen Therapeutics, Inc. Q3 2022 FastPack ® sales increased approximately 25% year-over-year Company continues to execute on and advance core therapeutic …See details»
Qualigen Therapeutics, Inc. Reports First Quarter 2021
May 14, 2021 Please submit questions for management no later than 10:00 a.m. EDT on Monday, May 17, 2021 to ir@qualigeninc.com. Speakers on the call from Qualigen will be …See details»
Qualigen Therapeutics, Inc. to present at the Benzinga
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for …See details»
Qualigen Therapeutics, Inc. Announces $12 Million Registered …
CARLSBAD, Calif., Dec. 16, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive …See details»
Therapeutics Pipeline - Qualigen Therapeutics
Our core therapeutics pipeline includes the following programs under active development for indications within rare oncology: QN-302 and Pan-RAS. To learn more about partnering or …See details»
Qualigen Therapeutics Announces Pre-IND Feedback from U.S.
CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused …See details»
Qualigen Therapeutics Receives Positive Pre-IND Response from …
Oct 28, 2020 Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19 Plans to File IND Application …See details»
FastPack® IP System Orders - Qualigen Diagnostics
©2024 Qualigen Diagnostics. Contact Us; Terms of Service; Privacy Policy; Scroll to TopSee details»